Avidity Biosciences, Inc. — Director's Dealing 2025

Aug 15, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2025-08-13

Reporting Person: Hughes Steven George (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-13	Common Stock	M	1542	$6.57	Acquired	40409	Direct
2025-08-13	Common Stock	S	1542	$46.66	Disposed	38867	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-13	Stock Option (Right to Buy)	$6.57	M	1542	Disposed	2033-09-10	Common Stock (1542)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

F2: This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.